Industrial Webinar Series: Microfluidic single B cell platform facilitate mAb discovery against multi-transmembrane

Please register the webinar via https://us06web.zoom.us/webinar/register/WN_jGAundHvSRSSCyT0__DYYw

1. Title: Microfluidic single B cell platform facilitates mAb discovery against multi-transmembrane proteins

   Abstract: The development of high-quality antibodies against multi-pass transmembrane proteins has always been a challenge in industry. These challenges include antigen preparation, efficient antibody screening, and rapid functional characterization of antibodies. Leveraging a microfluidic single B-cell antibody development platform, our team has effectively addressed the screening and functional characterization of high-quality antibodies as demonstrated in two case studies.

   Speaker: Dr. Hai Wu earned his master’s degree from Fudan University and his Ph.D. in Genetics from the Department of Medical Genetics at the University of Rochester. In 2014, he co-founded Yurogen, where he jointly developed and commercialized the SMab® single B-cell antibody development platform. Since 2021, Dr. Wu has served as Vice President and Chief Technology Officer of the Immunology Division at ABclonal.Under his leadership, ABclonal has become one of leading company in recombinant rabbit monoclonal antibody development and production, with broad portfolios including highly bioactive recombinant proteins, general research antibodies, high-quality IHC antibodies, flow cytometry antibodies, and multiplex assay reagents. These essential tools provide diverse solutions for research, diagnostics, and early-stage antibody drug development and clinical applications.

   
   

2. Title: Democratizing SPR systems for high performance modern drug discovery workflow

   Abstract: Surface Plasmon Resonance (SPR) is a gold-standard technique extensively used in drug discovery for the real-time, label-free analysis of biomolecular interactions. It is critical for characterizing binding affinity, kinetics, and specificity throughout the therapeutic development pipeline. However, its wider adoption in academic labs, biotech startups, and core facilities is often hindered by significant barriers. These include the high capital expenditure of commercial systems, steep learning curves associated with complex instrumentation and software, and vendor-locked ecosystems that is restrictive to lab automation. Polariton Life's SPR system is engineered specifically to address these limitations. We have developed a platform that breaks down the traditional barriers to access without compromising on data quality. Our instrument delivers best-in-class performance, offering high sensitivity and robust kinetic analysis, but does so at a fraction of the cost of incumbent systems. Furthermore, we prioritize intuitive user experience with streamlined software, significantly reducing the training and expertise required. By championing open, flexible architecture for our instruments and software, we empower researchers with greater choice and control. Polariton Life is thus making high-fidelity SPR technology more accessible, affordable, and user-friendly, accelerating its integration into the modern drug discovery workflow.

   Speaker: Dr. Ethan Yu is the founder and CTO of Polariton Life. With over 20 years of experience in optical biosensors, he holds a Ph.D. (Summa Cum Laude) from the Max-Planck-Institute for Polymer Research, followed by postdoctoral research at Stanford University. He previously led the development of the world's first equipment-free, quantitative CD4 test kit, earning Frost & Sullivan innovation award and grant funding from Gates Foundation. In 2020, he founded Polariton Life, aiming to commercialize high-end life science instruments. Under his leadership, Polariton Life has launched the S-CLASS SPR system, a high-throughput biomolecular interaction instrument, which is gaining wide adoption by leading academic and pharmaceutical institutions in China and US.

   
   

3. Title: Empowering Single B Cell Monoclonal Antibody Discovery: High-Throughput Plasma B Cell Screening with DPBIO’s CytoSpark®

   Abstract: The next generation of therapeutic discovery is being shaped by advances in single B cell monoclonal antibody screening and functional enzyme discovery. At DPBIO, we are leading this transformation with CytoSpark®, a cutting-edge high-throughput droplet microfluidics platform that enables rapid, functional screening at the single-cell level. Built around plasma B cell-based discovery, CytoSpark® offers direct screening capabilities for a wide range of species, -including rabbit, mouse, alpaca, and human- delivering faster timelines, higher diversity, and stronger functional outcomes compared to conventional approaches. The platform supports not only the discovery of antibodies against difficult targets such as membrane proteins and GPCRs, but also the identification of functional antibodies such as agonists, blockers, and neutralizers that go beyond simple binding. Beyond antibody discovery, CytoSpark® extends its power to enzyme evolution and functional screening, offering researchers a versatile tool to accelerate the development of novel biologics, cell lines, and synthetic biology applications. Through single-cell precision, high-throughput speed, and functional relevance, DPBIO is helping reshape the future of biopharmaceutical innovation.

   Speaker: Dr. Jennifer Sun is an innovation leader, entrepreneur, and scientist with over 20 years of experience spanning microfluidics, biomaterials, organ-on-a-chip, and advanced manufacturing. She is currently Global Director of Field Application Scientists at DPBIO, where she leads the implementation of droplet microfluidics platforms for antibody discovery and single-cell analysis.

   Dr. Sun holds a joint Ph.D. from Harvard University and Fudan University. She previously held leadership roles at Allegro 3D and BMF Precision, driving R&D, product development, and commercialization of novel biomedical technologies. Her contributions at Allegro 3D played a key role in positioning the company for its merger with Cellink and acquisition by BICO, a global leader in bioconvergence. An accomplished inventor and published researcher, Dr. Sun combines deep scientific expertise with entrepreneurial insight to translate innovations into impactful, real-world applications.